glp 1 receptor agonist use and risk of suicide death Glucagon-like peptide-1 agonists suicidality among patients with type 2 diabetes: active comparator, new user cohort study Postmarket safety profile of suicide/self-injury

Although rare, associations with nonarteritic anterior ischemic optic neuropathy, pancreatitis, medullary thyroid carcinoma, and acute kidney injury (AKI) have been reported, primarily through pharmacovigilance and case-based evidence

GLP-1 Data Survey 2025: GLP-1 Weight Loss, Types of GLP-1 Used, GLP-1 Duration Usage, GLP-1 Side Effects, Satisfaction & more.

Tirzepatide displayed an unprecedented glucose and body weight lowering potential, presenting also with the ability to increase insulin sensitivity, reduce systolic blood pressure and inflammation and ameliorate dyslipidemia, particularly by reducing triglycerides levels

Do not apply heat directly over the patch

Explore the mechanisms, clinical applications, and future opportunities of GLP-1 receptor agonists in drug development and disease management.

FDA is requesting that the risk be removed from the warnings and precautions section of labeling for the GLP-1 obesity drugs Eli Lilly and Co.s Zepbound (tirzepatide) and Novo Nordisk A/S Saxenda (liraglutide) and Wegovy (semaglutide).